At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT04296175Phase 3ActiveUpdate OverdueUpdated 15mo ago · Completion was 15mo agoA Prospective, Single Center, Randomized, Open-labled Stage III Clinical Trial Comparing the Efficacy and Safety of Anthracyclin Followed by Weekly Paclitaxel Versus Dose-dense Anthracyclin Followed by Weekly Paclitaxel Versus Dose-dense Anthracyclin Followed by Weekly Paclitaxel Combined With Carboplatin for High-risk, Triple-negative Early Breast Cancer
In Brief
A Phase 3 clinical trial evaluating Epirubicin, CTX, and 5 other interventions for Triple-negative Breast Cancer. Active but no longer recruiting, targeting 808 participants across 1 site.
Signals
Detailed Summary
This is a prospective, single center, randomized, open-labled stage III clinical trial comparing the efficacy and safety of anthracyclin followed by weekly paclitaxel versus dose-dense anthracyclin followed by weekly paclitaxel versus dose-dense anthracyclin followed by weekly paclitaxel combined with carboplatin for high-risk, triple-negative early breast cancer.
Study Details
Timeline
Interventions
90mg/m2, d1 every 2 or 3 weeks
600mg, d1 every 2 or 3 weeks
80mg/m2,d1,d8,d15, every 3 weeks
90mg/m2, d1 every 2 weeks
600mg, d1 every 2 weeks
80mg/m2,d1,d8,d15, every 4 weeks
AUC=2,d1,d8,d15, every 4 weeks